Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAO FOR

THE SIX MONTHS ENDED 30 JUNE 2020

On 25 August 2020, Dong-E-E-Jiao released its interim report for the six months ended 30 June 2020.

Dong-E-E-Jiao Company Limited（東阿阿膠股份有限公司）("Dong-E-E-Jiao") is a company incorporated in the People's Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") and approximately

23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited（華潤東阿阿膠有限公司）. The Group controls an

effective interest of approximately 22.31% of Dong-E-E-Jiao, which is accounted for as a subsidiary of the Company.

On 25 August 2020, Dong-E-E-Jiao released its interim report for the six months ended 30 June 2020 (the "Dong-E-E-JiaoUnaudited Financials"). Set out below is the key financial information of the Dong-E-E-Jiao Unaudited Financials:

As of

As of

30 June

31 December

Increase/

2020

2019

decrease

(RMB)

(RMB)

(%)

(unaudited)

(audited)

Total assets

11,194,805,066.24

11,653,674,527.93

-3.94%

Net assets attributable to shareholders of

the listed company

9,618,284,812.15

9,974,925,867.75

-3.58%

1

For the six months ended 30 June

Increase/

2020

2019

decrease

(RMB)

(RMB)

(%)

(unaudited)

(unaudited)

Revenue

1,095,177,753.22

1,890,344,562.13

-42.06%

Net profit attributable to the

-84,020,007.46

192,963,719.27

-143.54%

shareholders of the listed company

Net profit attributable to the

-105,261,773.21

143,923,347.62

-173.14%

shareholders of the listed company

(exclude extraordinary gains or losses)

Net cash flow from operating activities

360,489,007.66

-975,818,494.29

136.94%

Basic earnings per share (RMB/share)

-0.1295

0.3537

-136.61%

Diluted earnings per share (RMB/share)

-0.1295

0.3537

-136.61%

Weighted average return on net asset (%)

-0.79%

1.75%

-2.54

percentage

points

The Dong-E-E-Jiao Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group. Shareholders and potential investors should exercise caution when

dealing in securities of the Company and should not rely solely on such information.

For further details of the Dong-E-E-Jiao Unaudited Financials, please refer to the interim report for the six months ended 30 June 2020 published by Dong-E-E-Jiao on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board of Directors

China Resources Pharmaceutical Group Limited

WANG Chuncheng

Chairman

Shenzhen, 26 August 2020

As of the date of this announcement, the Board comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.

2

Attachments

  • Original document
  • Permalink

Disclaimer

China Resources Pharmaceutical Group Ltd. published this content on 26 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2020 23:56:16 UTC